Aldeyra Therapeutics (ALDX) Acquisitions (2019)
Aldeyra Therapeutics' (ALDX) quarterly Acquisitions came in at -$22626.0 in Q4 2019, down 132.45% quarter-over-quarter from $69728.0 in Q3 2019.
Powered by 
Analysis
Aldeyra Therapeutics (ALDX) Acquisitions (2019) Analysis & Trends
Aldeyra Therapeutics (ALDX) has reported Acquisitions for 1 consecutive years, with -$22626.0 the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Acquisitions changed N/A year-over-year to -$22626.0; the trailing twelve-month figure through Dec 2019 stood at $609464.0 (changed N/A YoY), and the FY2019 full-year result was $609464.0, changed N/A from the prior year.
- Acquisitions eased to -$22626.0 in Q4 2019 per ALDX's latest filing, from $69728.0 in the prior quarter.
- Across five years, Acquisitions topped out at $562362.0 in Q1 2019 and bottomed at -$22626.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Aldeyra Therapeutics | 89.28 Mn | 89.28 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -22,626.00 |
| Sep 30, 2019 | 69,728.00 |
| Mar 31, 2019 | 562,362.00 |